gilead.com

Webside score gilead.com

 Genereret December 14 2022 00:39 AM

Gammel data? OPDATER !

Scoren er 56/100





SEO Indhold

Titel

Gilead Sciences, Inc.

Længde : 21

Kan optimeres; Optimalt bør din titel indeholde mellem 40 og 70 karakterer (med mellemrum) Brug dette gratis redskab til at regne længden ud.

Beskrivelse

Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.

Længde : 153

Perfekt, din meta beskrivelse indeholder mellem 90 og 160 karakterer.

Nøgleord

Dårligt! Vi kan ikke finde nogle meta nøgleord på din side! Brug denne gratis online meta generator for at oprette nye nøgleord.

Og Meta Egenskaber

Godt, din side benytter Og egenskaberne

Egenskab Indhold
title Gilead Sciences, Inc.
description Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines.
image https://wwwam10.gilead.com/-/media/gilead-corporate/images/og/gilead_logo.jpg

Overskrifter

H1 H2 H3 H4 H5 H6
1 7 4 3 1 0
  • [H1] World AIDS Day: Striving Together Toward Equity
  • [H2] Contact
  • [H2] Creating a Better Healthier World
  • [H2] Connecting Breast Cancer Education to Community: Equal Hope
  • [H2] Latinas Contra Cancer Empowers Patients to Advocate for Change
  • [H2] Tatiana Williams Leads the Way with the Transinclusive Group
  • [H2] Social
  • [H2] Headline
  • [H3] Advancing Global Health
  • [H3] Sustainability
  • [H3] Partnerships and Community
  • [H3] Recent Stories
  • [H4] Community
  • [H4] Community
  • [H4] Community
  • [H5] Recent News

Billeder

Vi fandt 16 billeder på denne side.

Godt, de fleste eller alle af dine billeder har ALT tags.

Text/HTML balance

Balance : 40%

Optimalt! Denne sides text til HTML fordeling er mellem 25 og 70 procent.

Flash

Perfekt, ingen Flash objekter er blevet fundet på siden.

iFrame

Beklager! Din side har iFrames og det kan medføre i yderst dårlig læsning af søgerobotterne.

URL Omskrivning

Godt. Dine links ser venlige ud!

Underscores i links

Perfekt! Ingen underscores blev fundet i dine links

On-page links

Vi fandt et total af 161 links inkluderende 1 link(s) til filer

Anker Type Juice
Medicine Questions Ekstern Sender Juice
Report an Adverse Event Intern Sender Juice
Investors Intern Sender Juice
Contact Intern Sender Juice
Canada Ekstern Sender Juice
Mexico Intern Sender Juice
USA Intern Sender Juice
Argentina Intern Sender Juice
Brazil Intern Sender Juice
China Mainland Ekstern Sender Juice
Hong Kong Intern Sender Juice
India Intern Sender Juice
Japan Ekstern Sender Juice
Korea Ekstern Sender Juice
Singapore Intern Sender Juice
Taiwan Intern Sender Juice
Israel Ekstern Sender Juice
Saudi Arabia Intern Sender Juice
Türkiye Intern Sender Juice
United Arab Emirates Intern Sender Juice
South Africa Intern Sender Juice
Australia and New Zealand Intern Sender Juice
Austria Intern Sender Juice
Belgium and Luxembourg Ekstern Sender Juice
Czech Republic & Slovakia Intern Sender Juice
Denmark Intern Sender Juice
Finland Intern Sender Juice
France Ekstern Sender Juice
Germany Ekstern Sender Juice
Greece Intern Sender Juice
Iceland Intern Sender Juice
Ireland Intern Sender Juice
Italy Ekstern Sender Juice
Netherlands Intern Sender Juice
Norway Intern Sender Juice
Poland & The Baltics Intern Sender Juice
Portugal Intern Sender Juice
Romania Intern Sender Juice
Russia Intern Sender Juice
Spain Ekstern Sender Juice
Sweden Intern Sender Juice
Switzerland Intern Sender Juice
United Kingdom Ekstern Sender Juice
Mission and Core Values Intern Sender Juice
Partnerships and Community Intern Sender Juice
Inclusion and Diversity Intern Sender Juice
Corporate Giving Intern Sender Juice
Gilead Foundation Intern Sender Juice
Sustainability Intern Sender Juice
Advancing Global Health Intern Sender Juice
Medication Access Intern Sender Juice
Leadership Intern Sender Juice
How We Operate Intern Sender Juice
Ethics and Code of Conduct Intern Sender Juice
Therapeutic Areas Intern Sender Juice
Medicines Intern Sender Juice
Pipeline Intern Sender Juice
Research Intern Sender Juice
Clinical Trials Ekstern Sender Juice
Events Intern Sender Juice
Stories Intern Sender Juice
Newsroom Intern Sender Juice
Company Statements Intern Sender Juice
Annual Reports Intern Sender Juice
Careers at Gilead Intern Sender Juice
Our Culture Intern Sender Juice
Meet Our Employees Intern Sender Juice
Inclusion and Diversity in Hiring Intern Sender Juice
Compensation, Benefits and Wellbeing Intern Sender Juice
Our Global Footprint Intern Sender Juice
Early Career Opportunities Intern Sender Juice
Postdoctoral Fellowships Intern Sender Juice
Hiring Events Ekstern Sender Juice
Talent Community Sign-up Ekstern Sender Juice
Privacy Statements Intern Sender Juice
Terms Of Use Intern Sender Juice
Social Media Guidelines Intern Sender Juice
EU Data Disclosure Intern Sender Juice
Sitemap Intern Sender Juice
BACK TO MAIN MENU Intern Sender Juice
COMPASS Initiative Intern Sender Juice
HepConnect Intern Sender Juice
HIV Age Positively Intern Sender Juice
Lift Intern Sender Juice
RADIAN Intern Sender Juice
TRANScend Intern Sender Juice
What We Fund Intern Sender Juice
Funding Requests Intern Sender Juice
Zeroing In: Ending the HIV Epidemic Intern Sender Juice
Creating Possible Fund Intern Sender Juice
Our Business Is Sustainable Intern Sender Juice
Performance Intern Sender Juice
Reporting Intern Sender Juice
U.N. Global Compact Intern Sender Juice
U.N. Sustainable Development Goals Intern Sender Juice
COVID-19 Intern Sender Juice
HCV Elimination Intern Sender Juice
U.S. Patient Access Intern Sender Juice
Disaster Product Replacement Intern Sender Juice
Global Access Intern Sender Juice
Authorized Distributors Intern Sender Juice
ESG Goals Intern Sender Juice
Governance Intern Sender Juice
Transparency Intern Sender Juice
Policies Intern Sender Juice
Anti-Bribery and Anti-Corruption Policy Intern Sender Juice
Animal Use and Welfare Policy Intern Sender Juice
Disclosures Intern Sender Juice
Anti-Counterfeiting Intern Sender Juice
Consumer Product Safety Intern Sender Juice
Supplier Information Intern Sender Juice
Political Engagement Intern Sender Juice
Research Scholars Program Intern Sender Juice
Compassionate Use Intern Sender Juice
Investigator-Sponsored Research Intern Sender Juice
Press Releases Intern Sender Juice
Media Inquiries Intern Sender Juice
Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus Intern Sender Juice
Gilead Continues Efforts to Halt the Distribution of Counterfeit HIV Medications and Protect Patient Safety Intern Sender Juice
Veklury® (Remdesivir) Demonstrates Continued In Vitro Antiviral Activity Against Omicron Subvariants, Including BA.4 and BA.5 Intern Sender Juice
Sacituzumab Govitecan-Hziy Trodelvy Elevated to Category 1 Preferred Recommendation in Second-Line Metastatic Triple-Negative Breast Cancer Intern Sender Juice
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir Intern Sender Juice
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade Intern Sender Juice
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Intern Sender Juice
Gilead Statement on WHO Recommendation of Veklury® (Remdesivir) and Acceleration of Prequalification Submission Intern Sender Juice
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products Intern Sender Juice
Gilead to Expand Footprint in Oceanside Intern Sender Juice
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities Intern Sender Juice
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare Intern Sender Juice
Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain Intern Sender Juice
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia Intern Sender Juice
Veklury® (Remdesivir) Receives Positive CHMP Opinion for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Intern Sender Juice
Gilead Issues a Voluntary Nationwide Recall of Two Lots of Veklury® (Remdesivir) Due to Presence of Glass Particulates Intern Sender Juice
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant Intern Sender Juice
Gilead and Merck Announce Temporary Pause in Enrollment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir Intern Sender Juice
Gilead Announces Decision Not to Pursue Marketing Authorization for Descovy® for Pre-Exposure Prophylaxis in the European Union Intern Sender Juice
Gilead Statement on New NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Sacituzumab Govitecan-Hziy (Trodelvy®) in Second-Line and Later Metastatic Triple-Negative Breast Cancer Intern Sender Juice
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees Intern Sender Juice
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States Intern Sender Juice
Gilead Sciences Statement on Positive Phase 3 AMBITION Study Findings for the Treatment of HIV-Associated Cryptococcal Meningitis Intern Sender Juice
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B) Intern Sender Juice
Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Intern Sender Juice
Gilead Sciences Statement on Phase 3 Veklury® (Remdesivir) Intravenous Study in High Risk Non-Hospitalized Patients with COVID-19 Intern Sender Juice
Gilead Announces Additional Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Intern Sender Juice
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program Intern Sender Juice
Gilead Announces Plans for New Location in North Carolina’s Research Triangle Region Dedicated to Business Services Intern Sender Juice
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Intern Sender Juice
Gilead Sciences Statement on Recent Events in Washington, D.C. Intern Sender Juice
Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Intern Sender Juice
Gilead Sciences Statement on The World Health Organization’s Updated Veklury® (Remdesivir) COVID-19 Treatment Guidelines Intern Sender Juice
- Intern Sender Juice
- Intern Sender Juice
Year in Review 2021 Intern Sender Juice
Cookie Statement Intern Sender Juice
Partnership Request Intern Sender Juice
Gilead Sciences Again Named to Dow Jones Sustainability World Index Intern Sender Juice
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response Intern Sender Juice
- Ekstern Sender Juice
Stories@Gilead Intern Sender Juice
Investor Calls Intern Sender Juice
Modern Slavery Act Statement Intern Sender Juice

SEO Nøgleord

Nøgleords cloud

main      sciences      menu      hiv      gilead      together      community      statement      back      remdesivir     

Nøgleords balance

Nøgleord Indhold Titel Nøgleord Beskrivelse Overskrifter
gilead 37
back 16
main 16
menu 16
statement 16

Brugervenlighed

Link

Domæne : gilead.com

Længde : 10

FavIkon

Godt, din side har et FavIcon!

Printervenlighed

Vi kunne ikke finde en printer venlig CSS skabelon.

Sprog

Godt, dit tildelte sprog er en.

Dublin Core

Denne side benytter IKKE Dublin Core principperne.

Dokument

Dokumenttype

HTML 5

Kryptering

Perfekt. Dit Charset er tildelt UTF-8.

W3C Validering

Fejl : 12

Advarsler : 15

Email Privatliv

Advarsel! Mindst én email adresse er blevet fundet i rå tekst. Brug gratis antispam beskytter for at hemme din email fra spammere.

Udgået HTML

Godt! Vi har ikke fundet udgåede HTML tags i din kildekode

Hastigheds Tips

Alle tiders! Din webside bruger ikke nestede tabeller.
Advarsel! Din webside benytter inline CSS kode!
Godt, din website har få antal CSS filer
Dårligt, din webside har for mange JavaScript filer (mere end 6).
Perfekt, din hjemmeside udnytter gzip.

Mobil

Mobil Optimering

Apple Ikon
Meta Viewport Tag
Flash indhold

Optimering

XML Sitemap

Mangler

Dit websted ikke har en XML sitemap - det kan være problematisk.

Et sitemap lister URL'er, der er tilgængelige for gennemgang og kan indeholde yderligere oplysninger som dit websted seneste opdateringer, hyppigheden af ændringer, og betydningen af de webadresser. Dette gør det muligt søgemaskiner til at gennemgå webstedet mere intelligent.

Robots.txt

http://gilead.com/robots.txt

Stor, din hjemmeside har en robots.txt-fil.

Analytics

Mangler

Vi har ikke registrerer en analyseværktøj installeret på denne hjemmeside.

Web analytics kan du måle besøgendes aktivitet på dit websted. Du bør have mindst én analyseværktøj installeret, men det kan også være godt at installere et sekund for at krydstjekke data.

PageSpeed Insights

Apparat
Kategorier

Website Review

Website Review er et gratis SEO redskab der hjælper med din hjemmeside